Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Nov 9;15(22):5338.
doi: 10.3390/cancers15225338.

Evolution of Pharmacological Treatments and Associated Costs for Multiple Myeloma in the Public Healthcare System of Catalonia: A Retrospective Observational Study

Gemma Garrido-Alejos  1   2 , Guillem Saborit-Canals  3 , Laura Guarga  3 , Thais de Pando  3   4 , Miriam Umbria  3 , Albert Oriol  5 , Anna Feliu  6 , Caridad Pontes  1   3   4 , Antonio Vallano  1   3   7
Affiliations

Evolution of Pharmacological Treatments and Associated Costs for Multiple Myeloma in the Public Healthcare System of Catalonia: A Retrospective Observational Study

Gemma Garrido-Alejos et al. Cancers (Basel). .

Abstract

(1) Background: Our understanding of and treatment for multiple myeloma (MM) has advanced significantly, and new pharmacological treatments have promising benefits but high price tags. This study analyzes prescription patterns and pharmaceutical expenditure for MM treatments in Catalonia's public healthcare system over eight years. (2) Methods: A retrospective observational study examined MM treatment data from 2015 to 2022 in Catalonia, using healthcare registries from the Catalan Health Service to collect information on patients, medicines used, and treatment costs. (3) Results: A total of 4556 MM patients received treatment, with a rising trend in the number of treated patients each year from 902 in 2015 to 1899 in 2022. The mean age was 68.9 years, and patients were almost evenly distributed by gender (51.5% male). Most patients were treated with bortezomib (3338 patients), lenalidomide (2952), and/or daratumumab (1093). Most drugs showed increased utilization annually, most significantly for lenalidomide and daratumumab. The total pharmacological treatment cost throughout the entire study period was EUR 321,811,249, with lenalidomide leading with the highest total cost (EUR 157,236,784), and daratumumab exhibiting the highest increase in annual expenditure. (5) Conclusions: The study reveals a progressive increase in the number of MM patients treated and rising pharmaceutical costs. Lenalidomide and daratumumab incurred the highest costs. The findings highlight MM treatment's economic impact and the need to monitor prescription patterns and expenditures to optimize healthcare resources and decision making. Understanding these trends can guide resource allocation effectively.

Keywords: health expenditures; hematological neoplasms; multiple myeloma; pharmacological treatments; treatment patterns.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Annual number of treated multiple myeloma (MM) patients (incident and prevalent cases).
Figure 2
Figure 2
Annual number of MM patients treated with each medicine.
Figure 3
Figure 3
Annual pharmaceutical expenditure of MM for all medicines and by medicine.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Palumbo A., Anderson K. Multiple myeloma. N. Engl. J. Med. 2011;364:1046–1060. doi: 10.1056/NEJMra1011442. - DOI - PubMed
    1. Rajkumar S.V. Treatment of multiple myeloma. Nat. Rev. Clin. Oncol. 2011;8:479–491. doi: 10.1038/nrclinonc.2011.63. - DOI - PMC - PubMed
    1. Dimopoulos M.A., Moreau P., Terpos E., Mateos M.V., Zweegman S., Cook G., Delforge M., Hájek R., Schjesvold F., Cavo M., et al. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2021;32:309–322. doi: 10.1016/j.annonc.2020.11.014. - DOI - PubMed
    1. Dyba T., Randi G., Bray F., Martos C., Giusti F., Nicholson N., Gavin A., Flego M., Neamtiu L., Dimitrova N., et al. The European cancer burden in 2020: Incidence and mortality estimates for 40 countries and 25 major cancers. Eur. J. Cancer. 2021;157:308–347. doi: 10.1016/j.ejca.2021.07.039. - DOI - PMC - PubMed
    1. Palumbo A., Avet-Loiseau H., Oliva S., Lokhorst H.M., Goldschmidt H., Rosinol L., Richardson P., Caltagirone S., Lahuerta J.J., Facon T., et al. Revised international staging system for multiple myeloma: A report from international myeloma working group. J. Clin. Oncol. 2015;33:2863–2869. doi: 10.1200/JCO.2015.61.2267. - DOI - PMC - PubMed